IPSEN (OTCMKTS:IPSEY) Shares Gap Down – Here’s What Happened

IPSEN (OTCMKTS:IPSEY)’s share price gapped down prior to trading on Wednesday . The stock had previously closed at $49.15, but opened at $46.50. IPSEN shares last traded at $46.50, with a volume of 190 shares trading hands.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating on shares of IPSEN in a research report on Tuesday, June 30th. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of IPSEN in a research note on Thursday, May 14th. Barclays downgraded IPSEN from an “equal weight” rating to an “underweight” rating in a report on Tuesday. Zacks Research upgraded shares of IPSEN to a “hold” rating in a research note on Friday, May 29th. Finally, Jefferies Financial Group cut shares of IPSEN from a “hold” rating to a “moderate sell” rating in a research note on Sunday, August 2nd. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Reduce”.

IPSEN Trading Up 1.3%

The firm has a fifty day moving average of $46.60 and a 200-day moving average of $46.76.

IPSEN Company Profile

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).